Serum sickness-like reaction associated with mirabegron

Marcus G Tan, Bruce F Burns, Steven J Glassman
JAAD Case Reports 2019, 5 (6): 537-539
31205999
No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern. Cuong V Nguyen, Daniel D Miller Journal of Cutaneous Pathology 2017, 44 (2): 177-182
Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). Marta Rossanese, Giacomo Novara, Ben Challacombe, Alessandro Iannetti, Prokar Dasgupta, Vincenzo Ficarra BJU International 2015, 115 (1): 32-40
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). Osamu Yamaguchi, Hidehiro Kakizaki, Yukio Homma, Yasuhiko Igawa, Masayuki Takeda, Osamu Nishizawa, Momokazu Gotoh, Masaki Yoshida, Osamu Yokoyama, Narihito Seki, Akira Okitsu, Takuya Hamada, Akiko Kobayashi, Kentarou Kuroishi BJU International 2015, 116 (4): 612-22
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Christian Gratzke, Rob van Maanen, Christopher Chapple, Paul Abrams, Sender Herschorn, Dudley Robinson, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, Sang Jin Yoon, Salman Al-Shukri, Tomasz Rechberger, Elizabeth R Mueller European Urology 2018, 74 (4): 501-509
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Sender Herschorn, David Staskin, Le Mai Tu, Jonathan Fialkov, Terry Walsh, Katherine Gooch, Carol R Schermer Health and Quality of Life Outcomes 2018 April 19, 16 (1): 69
Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. Chung-Cheng Wang, Yung-Hong Jiang, Hann-Chorng Kuo Lower Urinary Tract Symptoms 2019, 11 (2): O180-O185
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). David Staskin, Sender Herschorn, Jonathan Fialkov, Le Mai Tu, Terry Walsh, Carol R Schermer International Urogynecology Journal 2018, 29 (2): 273-283
Patient-reported outcomes with the β 3 -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Vik Khullar, Gerard Amarenco, Javier C Angulo, Mary Beth Blauwet, Jameel Nazir, Isaac A Odeyemi, Zalmai Hakimi Neurourology and Urodynamics 2016, 35 (8): 987-994
The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Tao Wu, Xi Duan, Chen-Xi Cao, Chuan-Du Peng, Si-Yuan Bu, Kun-Jie Wang Urologia Internationalis 2014, 93 (3): 326-37
A drug safety evaluation of mirabegron in the management of overactive bladder. Dudley Robinson, Ganesh Thiagamoorthy, Linda Cardozo Expert Opinion on Drug Safety 2016, 15 (5): 689-96
Make the most of Read.
Download the mobile app.

Read by QxMD is copyright © 2022 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Remove bar
Read by QxMD icon Read
31205999
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

╳

We want to hear from doctors like you!

Take a second to answer a survey question.

╳